David A Cameron

List of Publications by Citations

218 papers	26,779 citations	68 h-index	163 g-index
231 ext. papers	31,170 ext. citations	10.3 avg, IF	6.22 L-index

#	Paper	IF	Citations
218	Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *New England Journal of Medicine*, **2005**, 353, 1659-72	59.2	3921
217	Lapatinib plus capecitabine for HER2-positive advanced breast cancer. *New England Journal of Medicine*, **2006**, 355, 2733-43	59.2	2641
216	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet, The*, **2014**, 384, 164-72	40	2177
215	2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. *Lancet, The*, **2007**, 369, 29-36	40	1177
214	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. *New England Journal of Medicine*, **2016**, 375, 1738-1748	59.2	975
213	Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. *Journal of the National Cancer Institute*, **2005**, 97, 1262-71	9.7	918
212	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. *Breast Cancer Research and Treatment*, **2008**, 112, 533-43	4.4	631
211	Identification of molecular apocrine breast tumours by microarray analysis. *Oncogene*, **2005**, 24, 4660-71	9.2	594
210	Triple-negative breast cancer: disease entity or title of convenience?. *Nature Reviews Clinical Oncology*, **2010**, 7, 683-92	19.4	588
209	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. *Lancet Oncology, The*, **2011**, 12, 236-44	21.7	500
208	11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. *Lancet, The*, **2017**, 389, 1195-1205	40	486
207	Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. *Lancet Oncology, The*, **2015**, 16, 266-73	21.7	485
206	A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. *Nature Medicine*, **2009**, 15, 68-74	50.5	477
205	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. *New England Journal of Medicine*, **2020**, 382, 597-609	59.2	396
204	Breast-cancer adjuvant therapy with zoledronic acid. *New England Journal of Medicine*, **2011**, 365, 1396-405	59.2	378
203	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. *Lancet, The*, **2013**, 382, 1021-8	40	377
202	Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. *Annals of Surgical Oncology*, **2012**, 19, 1508-16	3.1	329

201	Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. *Lancet Oncology, The*, **2013**, 14, 933-42	21.7	318
200	The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. *Human Reproduction*, **2006**, 21, 2583-92	5.7	278
199	Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. *Journal of Clinical Oncology*, **2008**, 26, 4883-90	2.2	261
198	1st International consensus guidelines for advanced breast cancer (ABC 1). *Breast*, **2012**, 21, 242-52	3.6	258
197	Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. *Oncologist*, **2010**, 15, 924-34	5.7	227
196	Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. *Lancet Oncology, The*, **2014**, 15, 997-1006	21.7	216
195	Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. *Annals of Oncology*, **2003**, 14, 1391-8	10.3	188
194	Breast cancer in pregnancy: recommendations of an international consensus meeting. *European Journal of Cancer*, **2010**, 46, 3158-68	7.5	186
193	Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. *Oncologist*, **2011**, 16, 1092-100	5.7	181
192	Pretreatment serum anti-m□lerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 1336-43	5.6	171
191	Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. *Lancet Oncology, The*, **2007**, 8, 1071-1078	21.7	170
190	Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). *Journal of Clinical Oncology*, **2014**, 32, 2159-65	2.2	164
189	Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. *Journal of Clinical Oncology*, **2008**, 26, 1948-55	2.2	156
188	Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. *Journal of Clinical Oncology*, **2005**, 23, 2988-95	2.2	147
187	Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. *Annals of Oncology*, **2008**, 19, 1090-6	10.3	146
186	Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. *Lancet, The*, **2009**, 373, 1681-92	40	144
185	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. *Lancet Oncology, The*, **2011**, 12, 1134-42	21.7	141
184	HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. *Clinical Cancer Research*, **2008**, 14, 7861-70	12.9	137

183	Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. *Journal of Clinical Oncology*, **2008**, 26, 1671-6	2.2	137
182	Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. *Journal of Clinical Oncology*, **2010**, 28, 1131-7	2.2	135
181	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. *Journal of Clinical Oncology*, **2020**, 38, 2610-2619	2.2	134
180	Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. *British Journal of Cancer*, **2005**, 92, 1869-76	8.7	134
179	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. *Lancet, The*, **2019**, 393, 2599-2612	40	131
178	Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. *British Journal of Cancer*, **2001**, 84, 1146-9	8.7	129
177	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). *Lancet Oncology, The*, **2013**, 14, 244-8	21.7	126
176	Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. *Clinical Cancer Research*, **2010**, 16, 2688-95	12.9	115
175	Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	114
174	Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. *Journal of Clinical Oncology*, **2007**, 25, 2006-11	2.2	112
173	Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). *Lancet Oncology, The*, **2010**, 11, 266-74	21.7	109
172	TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. *Lancet Oncology, The*, **2011**, 12, 527-39	21.7	101
171	Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. *British Journal of Cancer*, **2003**, 89, 1837-42	8.7	100
170	ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. *Contemporary Clinical Trials*, **2016**, 51, 56-64	2.3	99
169	Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. *Lancet Oncology, The*, **2015**, 16, 656-66	21.7	93
168	Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. *Breast Cancer Research*, **2010**, 12, R47	8.3	92
167	Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. *European Journal of Cancer*, **2013**, 49, 3404-11	7.5	90
166	Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. *Breast Cancer Research and Treatment*, **2011**, 127, 429-38	4.4	90

165	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. *European Journal of Cancer*, **2017**, 70, 146-155	7.5	88
164	Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. *Journal of Clinical Oncology*, **2000**, 18, 87-93	2.2	87
163	Increase in response rate by prolonged treatment with neoadjuvant letrozole. *Breast Cancer Research and Treatment*, **2009**, 113, 145-51	4.4	80
162	Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. *Journal of Clinical Oncology*, **2008**, 26, 5027-35	2.2	80
161	Breast Cancer Therapy Annual 2today? drug treatment of cancer?. *Breast Cancer Research*, **2003**, 6, 1	8.3	78
160	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. *Breast Cancer Research and Treatment*, **2006**, 99, 295-300	4.4	77
159	Letrozole as primary medical therapy for locally advanced and large operable breast cancer. *Breast Cancer Research and Treatment*, **2001**, 66, 191-9	4.4	75
158	Aromatase inhibitors and arthralgia. *Journal of Clinical Oncology*, **2001**, 19, 2767	2.2	75
157	Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. *Lancet Oncology, The*, **2020**, 21, 1296-1308	21.7	72
156	The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients. *Annals of Oncology*, **2004**, 15, 211-7	10.3	71
155	Continuous 5-fluorouracil in the treatment of breast cancer. *British Journal of Cancer*, **1994**, 70, 120-4	8.7	71
154	Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. *Cancer Chemotherapy and Pharmacology*, **1999**, 44, 453-60	3.5	69
153	Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. *Nature Clinical Practice Oncology*, **2008**, 5, 512-20		68
152	Maximizing clinical benefit with trastuzumab. *Seminars in Oncology*, **2004**, 31, 35-44	5.5	68
151	High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. *Gut*, **2017**, 66, 89-96	19.2	64
150	Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. *Annals of Oncology*, **2013**, 24, 355-361	10.3	64
149	Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. *Clinical Cancer Research*, **2009**, 15, 1487-95	12.9	64
148	Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. *Journal of the National Cancer Institute*, **2012**, 104, 56-66	9.7	64

147	Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy. *British Journal of Cancer*, **1997**, 76, 1099-105	8.7	60
146	Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. *Gynecologic Oncology*, **2007**, 106, 461-8	4.9	60
145	Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. *Journal of Clinical Oncology*, **2007**, 25, 4423-30	2.2	59
144	In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. *Breast Cancer Research and Treatment*, **2012**, 132, 463-70	4.4	58
143	Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. *Journal of the National Cancer Institute*, **2004**, 96, 1076-83	9.7	56
142	Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer. *Seminars in Oncology*, **2004**, 31, 45-50	5.5	56
141	Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?. *Breast Cancer Research and Treatment*, **2010**, 123, 805-14	4.4	53
140	Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. *Annals of Oncology*, **2008**, 19, 877-82	10.3	52
139	Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. *Molecular Cancer Therapeutics*, **2007**, 6, 93-100	6.1	51
138	Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. *Clinical Cancer Research*, **2007**, 13, 1438-44	12.9	50
137	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. *Journal of the National Cancer Institute*, **2018**, 110,	9.7	49
136	Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. *Breast Cancer Research and Treatment*, **2009**, 117, 577-89	4.4	49
135	The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. *Breast Cancer Research and Treatment*, **1997**, 44, 123-33	4.4	49
134	Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. *Journal of Steroid Biochemistry and Molecular Biology*, **2001**, 79, 103-7	5.1	49
133	The requirements of a specialist breast centre. *Breast*, **2020**, 51, 65-84	3.6	47
132	Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. *Journal of Clinical Oncology*, **2015**, 33, 1680-7	2.2	47
131	Current perspective - trastuzumab. *European Journal of Cancer*, **2009**, 45, 12-8	7.5	46
130	Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. *Journal of Clinical Oncology*, **2005**, 23, 8322-30	2.2	45

129	Lessons from the use of aromatase inhibitors in the neoadjuvant setting. *Endocrine-Related Cancer*, **1999**, 6, 227-30	5.7	44
128	Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence. *Pharmacoeconomics*, **2011**, 29, 415-32	4.4	42
127	Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. *Endocrine-Related Cancer*, **2006**, 13, 1121-33	5.7	42
126	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. *Health Technology Assessment*, **2016**, 20, xxiii-xxix, 1-201	4.4	42
125	Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase?. *British Journal of Cancer*, **2011**, 105, 1260-6	8.7	41
124	Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. *Breast Cancer Research and Treatment*, **1997**, 45, 99-107	4.4	41
123	Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. *Lancet Oncology, The*, **2017**, 18, 929-945	21.7	38
122	Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer. *British Journal of Cancer*, **2006**, 95, 1626-31	8.7	36
121	Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). *Journal of Clinical Oncology*, **2013**, 31, 2685-91	2.2	35
120	A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. *Clinical Breast Cancer*, **2009**, 9, 39-44	3	35
119	Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. *Breast Cancer Research*, **2010**, 12, R39	8.3	34
118	Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. *Carcinogenesis*, **2006**, 27, 729-39	4.6	34
117	Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. *European Journal of Cancer*, **2012**, 48, 3439-47	7.5	33
116	Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. *Lancet Oncology, The*, **2017**, 18, 1543-1552	21.7	32
115	A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer. *European Journal of Cancer*, **2014**, 50, 2367-74	7.5	31
114	Strengthening clinical cancer research in the United Kingdom. *British Journal of Cancer*, **2011**, 104, 1529-34	8.7	31
113	Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. *Journal of Clinical Oncology*, **2010**, 28, 960-6	2.2	31
112	Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. *Journal of Clinical Oncology*, **2008**, 26, 925-33	2.2	31

111	Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. *British Journal of Cancer*, **2008**, 99, 711-5	8.7	30
110	Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. *Journal of Clinical Oncology*, **2013**, 31, 1954-60	2.2	28
109	Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic?. *European Journal of Cancer*, **2009**, 45, 1733-43	7.5	28
108	Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. *Histopathology*, **2007**, 51, 219-26	7.3	28
107	Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. *Oncogene*, **2010**, 29, 5231-40	9.2	27
106	Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. *British Journal of Cancer*, **2007**, 97, 479-85	8.7	27
105	Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. *Journal of Pathology*, **2012**, 227, 481-9	9.4	26
104	Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 854-862	18.8	25
103	Chromosome instability and benefit from adjuvant anthracyclines in breast cancer. *British Journal of Cancer*, **2012**, 107, 71-4	8.7	25
102	Assessment of the effect of chemotherapy on ovarian function in women with breast cancer. *Journal of Clinical Oncology*, **2007**, 25, 1630-1; author reply 1632	2.2	25
101	Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-up. *Histopathology*, **2009**, 55, 724-31	7.3	24
100	Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. *British Journal of Cancer*, **1996**, 74, 2008-12	8.7	24
99	Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. *Journal of Pathology: Clinical Research*, **2016**, 2, 32-40	5.3	24
98	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. *Lancet Oncology, The*, **2021**, 22, 1139-1150	21.7	24
97	Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study. *European Journal of Cancer*, **2017**, 79, 226-234	7.5	23
96	Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. *Journal of the National Cancer Institute*, **2018**, 110, 871-879	9.7	23
95	Ibandronate: its role in metastatic breast cancer. *Oncologist*, **2006**, 11 Suppl 1, 27-33	5.7	22
94	Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. *Value in Health*, **2017**, 20, 1311-1318	3.3	21

93	Tamoxifen treatment failure in cancer and the nonlinear dynamics of TGFbeta. *Journal of Theoretical Biology*, **2004**, 229, 101-11	2.3	21
92	Trastuzumab-associated cardiac events in the Persephone trial. *British Journal of Cancer*, **2016**, 115, 1462-1470	8.7	20
91	Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience. *Clinical Drug Investigation*, **2006**, 26, 43-8	3.2	20
90	On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer. *Breast Cancer Research*, **2019**, 21, 73	8.3	19
89	Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance. *Molecular Endocrinology*, **2007**, 21, 2615-26		19
88	Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles. *Artificial Intelligence in Medicine*, **2019**, 97, 27-37	7.4	18
87	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.. *New England Journal of Medicine*, **2022**, 386, 942-950	59.2	18
86	Species differences in tumour responses to cancer chemotherapy. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2015**, 370,	5.8	17
85	Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. *European Journal of Health Economics*, **2012**, 13, 589-603	3.6	17
84	Advancing cancer drug discovery towards more agile development of targeted combination therapies. *Future Medicinal Chemistry*, **2012**, 4, 87-105	4.1	17
83	Breast cancer patientsQexperiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). *Breast*, **2004**, 13, 363-8	3.6	17
82	Impact of screening and risk factors for local recurrence and survival after conservative surgery and radiotherapy for early breast cancer: results from a large series with long-term follow-up. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 829-38	4	16
81	An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK. *Pharmacoeconomics*, **2009**, 27, 847-59	4.4	16
80	Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer. *British Journal of Cancer*, **2008**, 99, 1984-90	8.7	16
79	The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. *European Journal of Cancer*, **2008**, 44, 353-65	7.5	16
78	A prognostic index for operable, node-negative breast cancer. *British Journal of Cancer*, **2004**, 90, 1933-41	8.7	16
77	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.. *Lancet Oncology, The*, **2021**,	21.7	16
76	The p160 ER co-regulators predict outcome in ER negative breast cancer. *Breast Cancer Research and Treatment*, **2012**, 131, 463-72	4.4	15

75	Infusional 5-fluorouracil in breast cancer. *Cancer Treatment Reviews*, **1994**, 20, 357-64	14.4	15
74	Multi-omic machine learning predictor of breast cancer therapy response. *Nature*, **2021**,	50.4	15
73	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. *Journal of Clinical Oncology*, **2016**, 34, 936-44	2.2	14
72	Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments. *European Journal of Cancer*, **2021**, 144, 310-316	7.5	14
71	Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. *Lancet Oncology, The*, **2017**, 18, 755-769	21.7	13
70	Health economics in drug development: efficient research to inform healthcare funding decisions. *European Journal of Cancer*, **2010**, 46, 2674-80	7.5	13
69	Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. *British Journal of Cancer*, **2012**, 107, 1257-67	8.7	13
68	Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. *European Journal of Cancer*, **2018**, 90, 153-155	7.5	13
67	Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. *Breast*, **2003**, 12 Suppl 2, S22-9	3.6	12
66	Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. *British Journal of Cancer*, **2020**, 123, 852-859	8.7	11
65	Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response. *British Journal of Cancer*, **2000**, 83, 98-103	8.7	11
64	Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study. *Breast Cancer Research and Treatment*, **2010**, 122, 787-94	4.4	10
63	Cell killing and resistance in pre-operative breast cancer chemotherapy. *BMC Cancer*, **2008**, 8, 201	4.8	10
62	Patient management issues in metastatic bone disease. *Seminars in Oncology*, **2004**, 31, 79-82	5.5	10
61	Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. *Breast Cancer Research and Treatment*, **2013**, 138, 773-81	4.4	9
60	Locally advanced breast cancer: the outcome of primary polychemotherapy based on infusional 5 fluorouracil. *Breast*, **1999**, 8, 110-5	3.6	9
59	Mathematical modelling of tumour response in primary breast cancer. *British Journal of Cancer*, **1996**, 73, 1409-16	8.7	9
58	FKBPL: a marker of good prognosis in breast cancer. *Oncotarget*, **2015**, 6, 12209-23	3.3	9

57	Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer. *Clinical Advances in Hematology and Oncology*, **2007**, 5, 456-8	0.6	9
56	Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm. *Cancer Imaging*, **2010**, 10, 144-52	5.6	8
55	Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. *British Journal of Cancer*, **2019**, 120, 913-921	8.7	7
54	High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group. *British Journal of Cancer*, **1996**, 74, 2013-7	8.7	7
53	The challenges of making informed decisions about treatment and trial participation following a cancer diagnosis: a qualitative study involving adolescents and young adults with cancer and their caregivers. *BMC Health Services Research*, **2020**, 20, 25	2.9	7
52	Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. *BMC Cancer*, **2018**, 18, 391	4.8	6
51	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. *Breast Cancer Research and Treatment*, **2016**, 155, 127-32	4.4	6
50	Breast cancer chemoprevention: little progress in practice?. *Lancet, The*, **2014**, 383, 1018-20	40	6
49	Pertuzumab for the treatment of metastatic breast cancer. *Expert Review of Anticancer Therapy*, **2013**, 13, 907-18	3.5	6
48	Intraoperative radiotherapy for early breast cancer. *Lancet, The*, **2010**, 376, 1142; author reply 1143-4	40	5
47	The Royal College of Physicians Simms Lecture, 6 December 2011: clinical research networks and the benefits of intensive healthcare systems. *Clinical Medicine*, **2012**, 12, 446-52	1.9	5
46	Lapatinib for inflammatory breast cancer. *Lancet Oncology, The*, **2009**, 10, 538-9	21.7	5
45	Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?. *British Journal of Cancer*, **2002**, 87, 1365-9	8.7	5
44	Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer - An AZURE (BIG 01/04) sub-study. *Journal of Bone Oncology*, **2017**, 9, 48-54	4.5	4
43	Removing the primary tumour in metastatic breast cancer. *Lancet Oncology, The*, **2015**, 16, 1284-5	21.7	4
42	Bevacizumab: the first anti-angiogenic agent approved for the treatment of metastatic breast cancer. *European Journal of Cancer, Supplement*, **2008**, 6, 1-6	1.6	4
41	Postcode prescribing is alive and well in Scotland. *BMJ, The*, **2002**, 325, 101A	5.9	4
40	Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. *Breast Cancer Research and Treatment*, **2017**, 163, 507-515	4.4	3

39	Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer. *European Journal of Cancer*, **2017**, 72, 95-102	7.5	3
38	Expression of activated type I receptor tyrosine kinases in early breast cancer. *Breast Cancer Research and Treatment*, **2012**, 134, 701-8	4.4	3
37	Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case against. *Breast Cancer Research*, **2008**, 10 Suppl 4, S8	8.3	3
36	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. *Journal of Clinical Oncology*, **2021**, 39, 2720-2731	2.2	3
35	Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. *Breast Cancer Research and Treatment*, **2016**, 155, 303-11	4.4	2
34	Developing an international network for breast cancer research: the BIG experience. *Clinical Investigation*, **2011**, 1, 623-628		2
33	Modelling the Effects of Paclitaxel and Cisplatin on Breast and Ovarian Cancer. *Journal of Theoretical Medicine*, **2000**, 3, 11-23		2
32	A pilot study of infusional CMF (CMF-inf): active and well tolerated in breast cancer. The Edinburgh Breast Group. *Annals of Oncology*, **1996**, 7, 409-11	10.3	2
31	Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.. *Human Reproduction Update*, **2022**,	15.8	2
30	Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).. *Journal of Clinical Oncology*, **2022**, JCO2101918	2.2	2
29	Six versus 12 months of adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. *Health Technology Assessment*, **2020**, 24, 1-190	4.4	2
28	Breast cancer gene expression datasets do not reflect the disease at the population level. *Npj Breast Cancer*, **2020**, 6, 39	7.8	2
27	England's 30-day chemotherapy mortality: a measure of quality of care?. *Lancet Oncology, The*, **2016** , 17, 1172-3	21.7	2
26	Code of practice needed for samples donated by trial participants.. *Lancet Oncology, The*, **2022**, 23, e89-e90	21.7	2
25	Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial. *Breast Cancer Research and Treatment*, **2018**, 169, 497-505	4.4	1
24	Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?. *Breast Cancer Research*, **2013**, 15, R31	8.3	1
23	The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions. *European Journal of Cancer, Supplement*, **2012**, 10, 27-33	1.6	1
22	Foundation clinical trials. *Breast Cancer Research*, **2009**, 11 Suppl 3, S23	8.3	1

21	Role of bisphosphonate therapy in breast cancer and other advanced malignancies. *Breast*, **2003**, 12 Suppl 2, S20-1	3.6	1
20	Breast cancer vaccines: current research and future prospects. *Expert Review of Vaccines*, **2002**, 1, 29-34	5.2	1
19	Brachial plexopathy affecting the development of Beau's lines unilaterally. *Lancet Oncology, The*, **2001**, 2, 342	21.7	1
18	Treatment of Screen-Detected Breast Cancer: Can We Avoid or Minimize Overtreatment? **2016**, 375-401		1
17	Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8-11, 2020. *Breast Care*, **2021**, 16, 89-93	2.4	1
16	Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review.. *Breast*, **2022**, 63, 85-100	3.6	1
15	Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer. *British Journal of Cancer*, **2021**, 125, 1356-1364	8.7	0
14	Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial. *Cancer Research*, **2022**, 82, PD10-05-PD10-05	10.1	0
13	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.. *European Journal of Cancer*, **2022**, 166, 219-228	7.5	0
12	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. *Anticancer Research*, **2019**, 39, 797-802	2.3	
11	Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply. *Lancet, The*, **2020**, 395, 492-493	40	
10	Authors' reply. *Journal of Pathology*, **2013**, 229, e2-3	9.4	
9	Concerns about cardiotoxicity in the HERA trial - Authors' reply. *Lancet, The*, **2017**, 390, 2767-2768	40	
8	Lapatinib in the management of breast cancer. *Therapy: Open Access in Clinical Medicine*, **2009**, 6, 553-568		
7	Promises borne out in clinical studies. *European Journal of Cancer, Supplement*, **2008**, 6, 15-24	1.6	
6	Paclitaxel in early breast cancer: a viewpoint by David A. Cameron. *Drugs*, **2004**, 64, 1848-9	12.1	
5	Time for a change in breast cancer therapy?. *British Journal of Hospital Medicine*, **2004**, 65, 724-9		
4	Adjuvant Systemic Treatment for Breast Cancer: An Overview **2016**, 311-321		

3	Strategies for improving access to clinical trials by teenagers and young adults with cancer: A qualitative study of health professionals' views. *European Journal of Cancer Care*, **2021**, 30, e13408	2.4
2	Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα and cell-cycle signaling in a breast cancer model.. *Exploration of Targeted Anti-tumor Therapy*, **2022**, 3, 97-116	2.5
1	Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC). *Cancer Research*, **2022**, 82, PD9-08-PD9-08	10.1